ARS Pharmaceuticals【SPRY】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

15.041

買値

14.90

売値

15.05

出来高

1,399,252

14.3983 日の範囲 15.17

6.13 52 週間の範囲 18.49

時価総額

1.462B

前日終値

14.45

始値

14.62

時刻

最終取引時間

08:33:52

財務取引量

US$ 20,657,837

VWAP

14.7635

平均取引量 (3 か月)

1,317,515

発行済株式数

97,185,475

配当利回り

PER

-26.60

1 株当たり利益 (EPS)

-0.56

歳入

30k

純利益

-54.37M

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for pa... ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

ars-pharma.com

本社

Wilmington, Delaware, USA

設立

ARS Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker SPRY. The last closing price for ARS Pharmaceuticals was US$14.45. Over the last year, ARS Pharmaceuticals shares have traded in a share price range of US$ 6.13 to US$ 18.49.

ARS Pharmaceuticals currently has 97,185,475 shares in issue. The market capitalisation of ARS Pharmaceuticals is US$1.40 billion. ARS Pharmaceuticals has a price to earnings ratio (PE ratio) of -26.60.

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law...

Form 8-K - Current report

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an...

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO...

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.071	15.967617579	12.97	15.19	12.45	1543575	13.99148623	CS
4	4.521	42.9752851711	10.52	15.19	10.38	1419916	12.15920738	CS
12	-0.359	-2.33116883117	15.4	18.49	10.2	1317515	13.01138627	CS
26	4.001	36.240942029	11.04	18.49	8.9055	1203603	13.28939632	CS
52	8.761	139.506369427	6.28	18.49	6.13	918411	11.79985723	CS
156	9.761	184.867424242	5.28	18.49	2.55	753546	8.96315687	CS
260	9.761	184.867424242	5.28	18.49	2.55	753546	8.96315687	CS

SPRY - Frequently Asked Questions (FAQ)

What is the current ARS Pharmaceuticals share price?

The current share price of ARS Pharmaceuticals is US$ 15.041

How many ARS Pharmaceuticals shares are in issue?

ARS Pharmaceuticals has 97,185,475 shares in issue

What is the market cap of ARS Pharmaceuticals?

The market capitalisation of ARS Pharmaceuticals is USD 1.4B

What is the 1 year trading range for ARS Pharmaceuticals share price?

ARS Pharmaceuticals has traded in the range of US$ 6.13 to US$ 18.49 during the past year

What is the PE ratio of ARS Pharmaceuticals?

The price to earnings ratio of ARS Pharmaceuticals is -26.6

What is the cash to sales ratio of ARS Pharmaceuticals?

The cash to sales ratio of ARS Pharmaceuticals is 49.6k

What is the reporting currency for ARS Pharmaceuticals?

ARS Pharmaceuticals reports financial results in USD

What is the latest annual turnover for ARS Pharmaceuticals?

The latest annual turnover of ARS Pharmaceuticals is USD 30k

What is the latest annual profit for ARS Pharmaceuticals?

The latest annual profit of ARS Pharmaceuticals is USD -54.37M

What is the registered address of ARS Pharmaceuticals?

The registered address for ARS Pharmaceuticals is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801

What is the ARS Pharmaceuticals website address?

The website address for ARS Pharmaceuticals is ars-pharma.com

Which industry sector does ARS Pharmaceuticals operate in?

ARS Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
SXTP60 Degrees Pharmaceuticals Inc	US$ 1.18 (53.09%)	5.39M
LGCLLucas GC Ltd	US$ 0.77 (34.62%)	874.56k
PWMPrestige Wealth Inc	US$ 1.37 (28.04%)	370.34k
FFIEFaraday Future Intelligent Electric Inc	US$ 1.68 (24.44%)	5.34M
MFImF International Ltd	US$ 0.985 (16.68%)	2.24M
WBUYWeBuy Global Ltd	US$ 0.087 (-29.55%)	4.15M
EYENEyenovia Inc	US$ 0.0428 (-24.91%)	5.47M
MANHManhattan Associates Inc	US$ 222.00 (-24.77%)	77.96k
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0445 (-23.01%)	31.89M
MGOLMGO Global Inc	US$ 0.131399 (-20.99%)	13.56M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0445 (-23.01%)	31.89M
MGOLMGO Global Inc	US$ 0.131399 (-20.99%)	13.56M
RIMEAlgorhythm Holdings Inc	US$ 0.0287 (-7.12%)	13.15M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.50 (8.67%)	11.21M
ACONAclarion Inc	US$ 0.0271 (-14.51%)	8.42M